Safety and Efficacy of Implantation of Two Multifocal Intraocular Lenses in the Treatment of Senile Cataract
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02966496|
Recruitment Status : Unknown
Verified November 2016 by Qinghai University.
Recruitment status was: Active, not recruiting
First Posted : November 17, 2016
Last Update Posted : November 17, 2016
|Condition or disease||Intervention/treatment||Phase|
|Senile Cataract||Biological: Acri.LISA366D multifocal aspheric IOLs Biological: TecnisZ9001 multifocal aspheric IOLs||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Safety and Efficacy of Implantation of Two Multifocal Intraocular Lenses in the Treatment of Senile Cataract: a Randomized Controlled Clinical Trial|
|Study Start Date :||January 2016|
|Estimated Primary Completion Date :||June 2017|
|Estimated Study Completion Date :||December 2018|
Experimental: the test group
The patients aged 50-80 years will be randomly assigned to implantation of Acri.LISA366D multifocal aspheric IOLs in the test group.
Biological: Acri.LISA366D multifocal aspheric IOLs
The implantation of Acri.LISA366D multifocal aspheric IOLs are used in the test group.
Experimental: the control group
The patients aged 50-80 years will be randomly assigned to implantation of TecnisZ9001 multifocal aspheric IOLs in the control group.
Biological: TecnisZ9001 multifocal aspheric IOLs
The implantation of TecnisZ9001 multifocal aspheric IOLs are used in the test group.
- Number of cataract participants with good biocompatibility of intraocular lens implants [ Time Frame: month 12 after surgery ]Good engraftment, epithelialization, no neovascularization, retained transparency, no host inflammatory reaction.
- Visual acuity [ Time Frame: at month 1, month 3, month 6, month 12 and month 24 after surgery ]Best spectacle corrected visual acuity
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02966496
|Principal Investigator:||Ping Yu, Master||Affiliated Hospital of Qinghai University|